Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers by Bennett, A et al.
 on August 18, 2016http://rsob.royalsocietypublishing.org/Downloaded from rsob.royalsocietypublishing.orgResearch
Cite this article: Bennett A, Sloss O, Topham
C, Nelson L, Tighe A, Taylor SS. 2016 Inhibition
of Bcl-xL sensitizes cells to mitotic blockers,
but not mitotic drivers. Open Biol. 6: 160134.
http://dx.doi.org/10.1098/rsob.160134Received: 3 May 2016
Accepted: 8 July 2016Subject Area:
cellular biology
Keywords:
apoptosis, spindle checkpoint, paclitaxel,
taxol, WEHI-539Author for correspondence:
Stephen S. Taylor
e-mail: stephen.taylor@manchester.ac.uk†Present address: School of Environment and
Life Sciences, University of Salford, Salford M5
4WT, UK.
Electronic supplementary material is available
at http://dx.doi.org/10.1098/rsob.160134.& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Inhibition of Bcl-xL sensitizes cells to
mitotic blockers, but not mitotic drivers
Ailsa Bennett, Olivia Sloss, Caroline Topham†, Louisa Nelson, Anthony Tighe
and Stephen S. Taylor
Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester M20 4QL, UK
SST, 0000-0003-4621-9326
Cell fate in response to an aberrant mitosis is governed by two competing
networks: the spindle assembly checkpoint (SAC) and the intrinsic apoptosis
pathway. The mechanistic interplay between these two networks is obscured
by functional redundancy and the ability of cells to die either in mitosis or in
the subsequent interphase. By coupling time-lapse microscopy with selective
pharmacological agents, we systematically probe pro-survival Bcl-xL in
response to various mitotic perturbations. Concentration matrices show
that BH3-mimetic-mediated inhibition of Bcl-xL synergises with pertur-
bations that induce an SAC-mediated mitotic block, including drugs that
dampen microtubule dynamics, and inhibitors targeting kinesins and
kinases required for spindle assembly. By contrast, Bcl-xL inhibition does
not synergize with drugs which drive cells through an aberrant mitosis by
overriding the SAC. This differential effect, which is explained by compen-
satory Mcl-1 function, provides opportunities for patient stratification and
combination treatments in the context of cancer chemotherapy.1. Introduction
Antimitotic agents including the taxanes and vinca alkaloids are used exten-
sively to treat numerous malignancies, including ovarian and breast cancer as
well as various leukaemias [1]. Patient responses are, however, unpredictable;
some cancers are intrinsically resistant and others acquire resistance. In
addition, toxicity to the peripheral nervous system can be problematic [2].
To address these limitations, a raft of second-generation antimitotic agents has
been developed, including drugs targeting mitotic kinesins and mitotic kinases
[3–7]. Effective clinical use of these novel agents will require the development
of predictive biomarkers and patient stratification. This in turn will require an
in-depth understanding of the molecular mechanisms by which these drugs
kill cancer cells. At present, however, our understanding of the mechanisms by
which mitotic dysfunction leads to cell death is still in its infancy.
Traditional antimitotic agents and many second-generation drugs are mitotic
blockers [4]. By preventing spindle assembly, these drugs chronically activate the
spindle assembly checkpoint leading to a prolonged mitotic arrest which even-
tually leads to cell death, either directly during mitosis or following slippage
back into interphase [8]. Death in mitosis (DiM) and post-mitotic death (PMD)
both result from activation of the intrinsic apoptotic machinery, which is regu-
lated by pro-apoptotic and anti-apoptotic members of the Bcl-2 family [9–13].
On the pro-apoptotic side, the BH3-only proteins, Bim, Bid, Bad and Noxa,
have been shown to contribute to death in mitosis [14–17]. On the anti-apoptotic
side, Bcl-xL and Mcl-1 have been shown to be important mitotic survival factors
[18–23]. However, the relative importance of any given Bcl-2 family member is
complicated by two issues. First, there is considerable functional overlap
among both the pro- and anti-apoptotic factors [12,24–26]. Second, whether
these proteins act differently during DiM and PMD is often obscured by
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death in mitosis or following slippage.
Understanding the relative contributions of the various
Bcl-2 family members to mitotic cell fate is important from
an antimitotic chemotherapy perspective because several
pro-survival inhibitors are being evaluated as anti-cancer
drugs [27,28]. For example, the BH3 mimetic compound class
comprises several molecules that dock into a hydrophobic
groove of pro-survival Bcl-2 family proteins, thereby prevent-
ing binding of their pro-apoptotic BH3-only partners [29].
Frontrunners in this class include ABT-737 and ABT-263/
Navitoclax, related molecules that both inhibit three Bcl-2
family members, namely Bcl-2, Bcl-xL and Bcl-w. Notably,
Navitoclax accelerates apoptosis during mitotic arrest induced
by either taxol or inhibitors targeting the Eg5 kinesin [21]. In
addition, exposing the slippage-prone MDA-MB-231 breast
cancer cell line to ABT-737 induces death in mitosis [18].
In these cases, suppressing Bcl-xL using RNAi phenocopied
the BH3 mimetic, indicating that Bcl-xL plays an important
pro-survival role during a prolonged mitotic arrest.
More recently, novel BH3 mimetics have been developed
with enhanced specificity for individual pro-survival Bcl-2
family members, including ABT-199 (which targets Bcl-2
itself ) [30], A-1210477 (which targets Mcl-1) [31], and
WEHI-539 [32] plus a related compound, A-1155643 [33],
both of which target Bcl-xL. A-1155643 enhances the efficacy
of docetaxel in vitro and in mouse xenograft models [31],
further supporting the notion that Bcl-xL resists apoptosis
during a prolonged mitotic arrest. However, we recently
showed that WEHI-539 induces post-mitotic apoptosis
when RKO cells are treated with a low concentration of
taxol [12], indicating that Bcl-xL also supports survival fol-
lowing an abnormal mitosis. Therefore, to further explore
the role of Bcl-xL in the context of mitotic perturbations, we
set out to determine the relative contribution of Bcl-xL to sur-
vival following exposure to various antimitotic agents,
including mitotic blockers and drivers [4,34]. Moreover, to
determine Bcl-xL’s role during a prolonged mitotic arrest, fol-
lowing slippage and following an abnormal mitosis, we used
single-cell time-lapse imaging to directly correlate mitotic
behavior with subsequent cell fate [8].2. Results
2.1. Validation of WEHI-539 as an effective Bcl-xL
inhibitor
WEHI-539 was recently described as a potent and selective
Bcl-xL inhibitor [32]. As a BH3 mimetic, it docks into a hydro-
phobic groove of Bcl-xL, thereby blocking the binding of
Bcl-xL’s BH3-only partner proteins. To assess WEHI-539 as
a research tool in our experimental systems, we first per-
formed four validation experiments. For each we used RKO
colon cancer cells in which there is substantial functional
overlap between Bcl-xL and Mcl-1: while inhibition of
either in isolation has little impact, inhibiting both is suffi-
cient to induce apoptosis in the absence of cytotoxic insult
[12] (see the electronic supplementary material, figure S1a).
To measure apoptosis, we used time-lapse imaging and cell
fate profiling in conjunction with a fluorescent caspase 3/7
reporter [8,12]. First, we reasoned that if WEHI-539 is selec-
tive for Bcl-xL over Mcl-1, then it should only induceapoptosis in RKO cells in the absence of Mcl-1. Indeed,
while WEHI-539 alone was relatively benign up to concen-
trations of 5 mM (electronic supplementary material, figure
S1a), following Mcl-1 RNAi, 100 nM was sufficient
to induce extensive apoptosis (figure 1a; electronic
supplementary material, figure S1a).
Bcl-xL sequesters multiple BH3-only proteins, including
the apoptosis activator Bim which is involved in taxol sensi-
tivity [12,35,36]. Secondly, therefore, we asked whether
WEHI-539 exacerbated the ability of a tet-responsive Bim
transgene to induce apoptosis (electronic supplementary
material, figure S1b). Indeed, while induction of Bim with
30 ng ml21 tetracycline only induced moderate apoptosis,
100 nM WEHI-539 substantially enhanced the effect
(figure 1b). Note that Bim overexpressing cells exposed to
WEHI-539 typically died very shortly after mitosis (electronic
supplementary material, figure S1b), an issue we return to in
the Discussion.
Thirdly, we asked whether WEHI-539 blocked the binding
of Bcl-xL to its partner BH3-only proteins. Indeed, when we
affinity-purified GFP-tagged Bcl-xL in the presence of
100 nM WEHI-539, levels of co-purifying Bim, Bad, Bax and
Bak were all reduced (figure 1c; electronic supplementary
material, figure S1c). And finally, because overexpression of
a tet-responsive Bcl-xL transgene potently resists taxol-
induced apoptosis [12], we askedwhetherWEHI-539 reversed
this effect. Indeed, while induction of Myc-tagged Bcl-xL with
100 ng ml21 tetracycline completely blocked taxol-induced
apoptosis, this was reversed by 100 nM WEHI-539
(figure 1d; electronic supplementary material, figure S1d ).
Thus, these observations confirm that WEHI-539 behaves as
one would expect for a potent and selective Bcl-xL inhibitor.
Because we previously showed that Bcl-xL overexpression
resists apoptosis both in mitosis and following slippage [12],
we were interested to determine whether the effect of
WEHI-539 in the context of Bcl-xL overexpression was via
restoration of DiM or PMD. Cell fate profiling showed that
in the presence of taxol, 86% of RKO cells underwent DiM
and only 14% slipped (figure 1e). Every cell that slipped
then underwent PMD, with an average of 18.5 h between
mitotic exit and death. Consistent with our prior observations
[12], overexpression of Bcl-xL dramatically shifted the balance
from DiM to slippage, with 94% undergoing slippage. Of
these, only 6% underwent PMD, with an average onset
time of 26 h. Interestingly, while 50 and 100 nM WEHI-539
only marginally reversed the balance back towards DiM,
these concentrations had a major impact on PMD, increasing
both the frequency and accelerating its onset (figure 1e). By
contrast, 500 nM WEHI-539 completely shifted the balance
back in favour of DiM. Thus, these observations confirm
that Bcl-xL is a potent pro-survival factor both during a
prolonged mitotic arrest and following slippage.2.2. WEHI-539 sensitizes cells to microtubule-binding
agents
Having validated WEHI-539 as a valuable research tool to
probe Bcl-xL function in the context of mitotic cell fate, we
set out to determinewhether it sensitized cancer cells to various
mitotic blockers, initially focusing on the microtubule-binding
agents taxol and nocodazole. RKO cells were exposed to a
matrix of increasing drug concentrations, then caspase 3/7
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Figure 1. Validation of WEHI-539 as an effective Bcl-xL inhibitor. (a) Line graph showing apoptosis induction over a 72 h time course after RKO cells were trans-
fected with siRNAs targeting Mcl-1 for 24 h before exposure to 100 nM WEHI-539. (b) Line graph showing apoptosis induction following expression of Bim with
30 ng ml21 tetracycline (Tet) and exposure to 100 nM WEHI-539. (c) Immunoblots showing affinity purification of GFP-tagged Bcl-xL induced with 100 ng ml21
tetracycline in the presence and absence of 100 nM WEHI-539, and detection of co-purifying Bim, Bad, Bak and Bax. Note that 100 nM WEHI-539 diminishes binding
of pro-apoptotic proteins. (d ) Line graph showing apoptosis induction by 100 nM taxol, suppression by the induction of Myc-tagged Bcl-xL, and restoration by
100 nM WEHI-539. (e) Cell fate profiles of RKO cells exposed to 100 nM taxol following induction of Myc-tagged Bcl-xL and exposure to increasing concentrations
of WEHI-539. The number of cells undergoing death in mitosis (red), slippage (blue) and PMD (green) is quantitated in the bar graph. For the cells that undergo
PMD, the scatter plot shows the time from mitotic exit to death. *p, 0.05. Zero hours on the fate profiles represents when cells entered mitosis.
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course (figure 2a). As shown above, WEHI-539 alone was
relatively benign but, as anticipated, taxol and nocodazole
induced apoptosis in dose-dependent manners. Importantly,
the matrix approach readily identified concentrations where
the combination dramatically enhanced apoptosis. Specifi-
cally, while 10 nM taxol and 20 ng ml21 nocodazole onlyinduced apoptosis to 46% and 23% of the maximum, respect-
ively, inclusion of 100 nM WEHI-539 induced near-maximal
cell death (figure 2b). At these relatively low concentrations
of antimitotic drug, while many RKO cells underwent DiM,
rather than slipping the remainder eventually completed cell
division (figure 2c). In taxol, some of the dividers underwent
PMD but in nocodazole they all arrested in the next
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Figure 2. WEHI-539 sensitizes cells to microtubule-binding agents. (a) Concentration matrices showing apoptosis induction over a 72 h time course following
exposure of RKO cells to either taxol or nocodazole and WEHI-539. (b) Line graphs showing apoptosis induction following exposure to 10 nM taxol or
20 ng ml21 nocodazole (Noc) plus 100 nM WEHI-539. (c) Cell fate profiles of cells as treated in (b). For those cells undergoing death in mitosis, the scatter
plots quantitate the time from mitotic entry to cell death. #p , 0.0001. Zero hours on the fate profiles represents when cells entered mitosis.
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enhanced apoptosis differed between the two mitotic block-
ers. In taxol, WEHI-539 had two effects, accelerating DiM by
approximately 3.5 h and increasing the frequency of PMD(figure 2c). By contrast, WEHI-539 did not accelerate DiM in
nocodazole-treated cells but rather induced PMD in every
cell that divided. Nevertheless, despite these differences,
these observations build on prior reports [37], and
r5
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mitotic blockers
Like the microtubule-binding agents, several second-generation
antimitotic drugs also block mitotic progression by disrupting
spindle assembly [3,4]. These include inhibitors targeting
mitotic kinesins, such as Eg5 and Cenp-E, and mitotic kinases
such as Plk1. We therefore asked whether pharmacological
inhibition of Bcl-xL also sensitized cells to agents targeting
these mitotic regulators, focusing on the Eg5 inhibitor AZ138
[8], the Plk1 inhibitor BI 2536 [38] and the Cenp-E inhibitor
GSK923295 [39]. As above, RKO cells were analysed following
exposure to a matrix of increasing drug concentrations, which
again readily identified combinatorial concentrations that
enhanced apoptosis (electronic supplementary material, figure
S2a). To define this phenomenon in more detail, we performed
cell fate profiling at concentrations where the enhancement of
apoptosis was particularly marked.
In the case of the Eg5 inhibitor, sensitivity to 200 nMAZ138
was enhanced by 100 nMWEHI-539 (figure 3a). Note however
that 1 mMAZ138 is typically required to induce a potentmitotic
block [8]. Indeed, at 200 nM, while 54% underwent DiM and
6% slipped, 40% eventually divided (figure 3b). As above
with nocodazole, these dividers never entered another mitosis,
suggesting cell cycle arrest. Notably, in the presence of 100 nM
WEHI-549, 68% of the dividers underwent apoptosis
(figure 3b). Thus, Bcl-xL inhibition sensitizes RKO cells to Eg5
inhibition by enhancing PMD rather than DiM. The ability of
WEHI-539 to enhance apoptosis was particularly striking in
the case of the Plk1 inhibitor BI 2536; whereas 50 nM alone
only induced 21% apoptosis, 100 nM WEHI-539 increased
this to 70% (figure 3a). As with nocodazole and the Eg5 inhibi-
tor, WEHI-539 did not significantly accelerate the time to DiM
but rather induced PMD following slippage or cell division
(figure 3b,c). As above, at the relatively low concentration of
50 nM BI 2536, a substantial proportion of cells eventually
divided (figure 3b). Therefore, we asked what happened at
higher concentrations of BI 2536, which induced a potent cell
division block. At 500 nM, the majority of cells underwent
DiM or PMD after slippage (electronic supplementarymaterial,
figure S2b). Of those cells that slipped, 78% of cells underwent
PMD after an average of 9.1 h (figure 3d).When 100 nMWEHI-
539 was included, PMD was accelerated to 2.4 h (figure 3d;
electronic supplementary material, figure S3b). Note that, para-
doxically, at BI 2536 concentrations above 500 nM, apoptosis
induction was reduced (electronic supplementary material,
figure S2a), most probably due to suppression of mitotic
entry [40]. Nevertheless, as with the Eg5 inhibitor, WEHI-539
sensitizes RKO cells to Plk1 inhibition largely by enhancing
PMD. This phenomenon was strikingly apparent with the
Cenp-E inhibitor. At 100 nM GSK923295, 66% of cells even-
tually divided, 21% of which then underwent PMD after an
average of 12.6 h (figure 3b–d). Upon inclusion of 100 nM
WEHI-539, 97% of the dividers underwent PMD after
an average 3.6 h. Thus, together with the observations
described above, these data demonstrate that inhibiting Bcl-
xL can sensitize cells to second-generation mitotic blockers,
largely by enhancing post-mitotic cell death.2.4. WEHI-539 only has a minor impact when
combined with mitotic drivers
In contrast to the microtubule-binding agents, several second-
generation antimitotic drugs do not trigger a prolonged
mitotic arrest, but rather drive cells through an abnormal
division [4]. These include drugs targeting Aurora A,
Aurora B and Mps1. To determine whether inhibiting
Bcl-xL also sensitized cells to these drugs, we analysed
WEHI-539 in combination with the Aurora A inhibitor
MLN8054 [41], the Aurora B inhibitor ZM447439 [42] and
the Mps1 inhibitor AZ3146 [43]. In isolation, all three drugs
induced the expected phenotypes; MLN8054 induced a tran-
sient mitotic delay followed by cell division, ZM447439
induced a transient delay followed by cytokinesis failure
and AZ3146 accelerated mitotic exit (figure 4a,c). While inhi-
biting Aurora A or Aurora B alone was not sufficient to
induce apoptosis, at least during the 72 h time course,
the Mps1 inhibitor induced PMD in 38% of cells (figure 4c).
Interestingly, the concentration matrices failed to identify
combinations where WEHI-539 significantly enhanced
apoptosis (not shown). Even at relatively high concentrations
of mitotic driver, WEHI-539 had little additional effect
especially in the case of the two Aurora kinase inhibitors
(figure 4b,c). WEHI-539 did have a minor effect when com-
bined with Mps1 inhibitor, increasing PMD to 62% and
accelerating its onset by 4 h, although this latter difference
was not statistically significant (data not shown). Thus,
while pharmacological inhibition of Bcl-xL convincingly
sensitizes cells to mitotic blockers, it only has a minor effect
when combined with mitotic drivers.
To explore this notion further, we used the concentration
matrices to perform a Bliss independence analysis [44,45],
and represented the data as heat maps with positive Bliss
excess values coloured green and negative values red (elec-
tronic supplementary material, figure S3). The heat maps for
the microtubule toxins AZ138, BI 2536 and GSK923295 are
characterized by patches of green (i.e. positive Bliss excess
scores). By contrast, the heat maps for MLN8054, ZM447439
and AZ3146 are dominated by negative values, further sup-
porting the notion that inhibiting Bcl-xL has little impact in
the context of a mitotic driver. Accordingly, the mitotic block-
ers all returned high Bliss sum values, while MLN8054 and
ZM447439 returned negative Bliss sums (electronic sup-
plementary material, figure S3b). AZ3146 gave a positive
albeit low Bliss sum, consistent with the observation that it
enhances PMD to some extent (figure 4c). Thus, this analysis
confirms the notion that while pharmacological inhibition of
Bcl-xL sensitizes cells to mitotic blockers, this effect is considerably
less pronounced when combined with mitotic drivers.
2.5. Overexpression of Mcl-1 suppresses WEHI-539-
induced post-mitotic death
To rationalize the differential effect Bcl-xL inhibition had on
mitotic blockers versus mitotic drivers, we turned our atten-
tion to Mcl-1, a pro-survival factor that is degraded during
a prolonged mitotic arrest [46–49] (see the electronic sup-
plementary material, figure S4b). We reasoned that if both
Mcl-1 and Bcl-xL promote post-mitotic survival, then degra-
dation of Mcl-1 during a prolonged mitotic arrest could
account for why cells treated with mitotic blockers become
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gely depleted during a nocodazole arrest, its levels
remained high in the presence of ZM447439 (electronic
supplementary material, figure S4b). Therefore, to test this
hypothesis further, we modulated Mcl-1 levels in RKO
cells and asked whether this altered their sensitivity to
combinations of antimitotic agents plus WEHI-539.First, we generated an RKO cell line expressing a tet-inducible
GFP-tagged Mcl-1 transgene in order to overexpress Mcl-1
(electronic supplementary material, figure S4a). When
uninduced control cells were exposed to 20 ng ml21 of nocoda-
zole, the vast majority of cells arrested for an average of 4 h
then divided (figure 5a). Of these, only 17% underwent PMD
after an average of 32 h. Consistent with observations shown
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majority of dividers (figure 5a). Overexpression of Mcl-1 only
had a minor impact in the absence of WEHI-539, prolonging
time to death in the few cells that underwent DiM. However,
Mcl-1 overexpression had a significant impact in the presence
of WEHI-539, substantially prolonging the onset of PMD in
a subset of the cells, extending the average time to PMD
from 2.8 to 17.5 h (figure 5b). Thus, elevating Mcl-1 suppresses
post-mitotic sensitivity to WEHI-539, consistent with the notion
that a prolonged mitotic arrest sensitizes cells to Bcl-xL
inhibitors by degrading Mcl-1.Open
Biol.6:1601342.6. Inhibition of Mcl-1 sensitizes cells to WEHI-539
plus an Aurora B inhibitor
Next, we suppressed Mcl-1 by RNAi and asked whether this
sensitized Bcl-xL-inhibited cells to a mitotic driver. Consist-
ent with the data in figure 4c, adding WEHI-539 to the
Aurora B inhibitor ZM447439 had little effect. However,
when Mcl-1 was suppressed by RNAi, apoptosis was
induced in the majority of cells, either during mitosis or fol-
lowing cell division failure (electronic supplementary
material, figure S4c). However, this experiment is compli-
cated because co-inhibition of Mcl-1 and Bcl-xL in RKO
cells is sufficient to induce apoptosis even in the absence
of extrinsic insult [12] (see the electronic supplementary
material, figure S1a). Indeed, despite reducing the concen-
tration of siRNAs targeting Mcl-1 to 25 nM, when
combined with 100 nM WEHI-539, the vast majority of
cells died, either in mitosis or shortly thereafter (electronic
supplementary material, figure S4c). In fact, the addition
of the Aurora B inhibitor actually conferred protection,
reducing the number of cells dying in mitosis and delaying
PMD, possibly due to suppressing telomere deprotection
[12,50] (see Discussion). Therefore, to enable better titration
of Mcl-1 function, rather than RNAi we turned to the Mcl-1
inhibitor, A-1210477 [31]. Like WEHI-539, A-1210477 is a
BH3-mimetic and inhibits Mcl-1 from binding its pro-
apoptotic partners (electronic supplementary material,
figure S4d ). First, we analysed a concentration matrix to
identify a combinatorial concentration of WEHI-539 and
A-1210477 that induced minimal apoptosis (electronic sup-
plementary material, figure S4e). When used in isolation,
100 nM WEHI-539 and 2 mM A-1210477 did not suppress
proliferation or induce apoptosis, and in combination only
had a minor effect (electronic supplementary material,
figure S4e). Cell fate profiling confirmed that 2 mM
A-1210477 in isolation or in combination with ZM447393
had little effect (figure 5c). When combined with WEHI-
539, 2 mM A-1210477 induced apoptosis in 44% of cells.
However, addition of ZM447439 greatly enhanced this,
increasing the apoptotic fraction to 86% and accelerating
the average time from mitotic exit to death from 35 h to
10 h (figure 5c,d ). Thus, despite the technical difficulties
inherent when suppressing both Mcl-1 and Bcl-xL, these
observations show that Mcl-1 promotes post-mitotic survi-
val when Bcl-xL-inhibited cells are driven through an
abnormal division. In turn, this supports the hypothesis
that RKO cells become dependent on Bcl-xL function after
exiting a protracted mitosis due to degradation of Mcl-1
during the delay.2.7. Mcl-1-deficient DLD-1 cells are sensitive to WEHI-
539 when combined with ZM447439
If both Mcl-1 and Bcl-xL support post-mitotic survival when
cells are exposed to mitotic drivers, then we reasoned that cell
lines already deficient for Mcl-1 should be sensitive to the
combination of a Bcl-xL inhibitor plus a mitotic driver.
To test this, we turned to DLD-1 cells, another colon cancer
cell line which, compared with RKO, has a relatively lower
level of Mcl-1 [49]. In contrast to RKO, exposing DLD-1
cells to WEHI-539 and ZM447439 separately was sufficient
to induce apoptosis in a fraction of cells (figure 5e,f ), consist-
ent with weakened Mcl-1 function. More importantly,
however, combining WEHI-539 with ZM447439 induced
PMD in 76% of cells. Thus, in a cell line lacking robust
Mcl-1 function, post-mitotic survival in the presence of a
mitotic driver is dependent on Bcl-xL function.3. Discussion
Bcl-xL has previously been implicated as an important mito-
tic survival factor [12,18,20–22]. To further refine our
understanding of Bcl-xL’s role when mitosis is disrupted,
we have taken advantage of WEHI-539, a BH3 mimetic that
selectively and potently blocks binding of Bcl-xL to its BH3-
only pro-apoptotic partner proteins [32]. Using concentration
matrices to combine WEHI-539 with a panel of representative
antimitotic agents, we have systematically analysed Bcl-xL’s
pro-survival potential in response to drugs that either block
or accelerate mitotic progression. In addition, by using cell
fate profiling we were able to differentiate death in mitosis
from post-mitotic apoptosis. Our results demonstrate that
Bcl-xL sustains survival following perturbations that induce
a prolonged mitotic delay. By contrast, Bcl-xL function is
less critical when cells are driven through an abnormal mito-
sis, most probably due to the compensatory action of Mcl-1.
3.1. Both Bcl-xL and Mcl-1 promote survival following
an aberrant mitosis
During mitosis, transcription and translation are heavily
suppressed. Indeed, the regulation of mitotic progression is
governed largely by post-translational modifications, in par-
ticular protein phosphorylation and ubiquitin-mediated
proteolysis [51–53]. Accordingly, the apoptotic proteome is
also extensively modified during mitosis; for example,
Caspase-9, Bid and Bcl-xL are phosphorylated by mitotic
kinases [16,22,54–56]. Pro-apoptotic Bim is ubiquitinated by
the anaphase-promoting complex (APC/C), the E3 ubiquitin
ligase that also targets Cyclin B1 for degradation [15]. How-
ever, the net physiological effect these post-translational
modifications have on the apoptotic threshold is unclear.
Moreover, how these modifications change during a delayed
or abnormal mitosis is also not clear. An exception is pro-
survival Mcl-1, with several independent reports showing
that it is slowly degraded during a checkpoint-mediated
mitotic arrest [46,48,49]. Mcl-1 degradation is proteasome
dependent and while several E3 ligases have been implicated,
the exact mechanism remains to be delineated [49,57]. Never-
theless, several independent observations support the notion
that Mcl-1 degradation serves as a mitotic ‘death timer’
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when mitotic exit is blocked in RKO cells by expression of a
non-degradable Cyclin B1 mutant, Mcl-1 RNAi accelerates
DiM [49]. Conversely, overexpressing Mcl-1 delays taxol-
induced DiM by over 5 h. Modulating Mcl-1 also influences
post-mitotic survival. We recently showed that Mcl-1 RNAi
in slippage-prone DLD-1 cells increases the frequency of
apoptosis after slippage, while overexpressing it delays
PMD [49]. Taken together with the functional overlap
between Mcl-1 and Bcl-xL [12,24,25], these observations
allowed us to formulate a simple hypothesis to account for
why pharmacological inhibition of Bcl-xL sensitized cells to
mitotic blockers but not mitotic drivers, namely that degra-
dation of Mcl-1 during the prolonged delay induced by a
blocker renders cells more dependent on Bcl-xL when they
eventually exit mitosis. Our subsequent experiment showing
that simultaneous inhibition of Bcl-xL and Mcl-1 accelerates
PMD in response to an Aurora B inhibitor supports this
hypothesis. In turn, this further supports the notion that
both Bcl-xL and Mcl-1 contribute to survival following an
aberrant mitosis.3.2. In the absence of robust pro-survival activity,
mitosis induces apoptosis
Consistent with their overlapping function, simultaneous
inhibition of Bcl-xL and Mcl-1 can induce apoptosis even in
the absence of cytotoxic insult. This has been shown
previously by others [24], but we noted recently that
co-repression of Bcl-xL and Mcl-1 by RNAi causes RKO
cells to die either in mitosis or very shortly following mitotic
exit [12]. Here, we made a similar observation: in the absence
of any additional exogenous stress, Mcl-1 RNAi cells exposed
to WEHI-539 died either in mitosis or very shortly after mito-
tic exit. This does not appear to be an RNAi-related
phenomenon; when both Bcl-xL and Mcl-1 were inhibited
pharmacologically, using WEHI-539 and A-1210477, apopto-
sis occurred frequently in mitosis or shortly thereafter (not
shown). Moreover, when cells overexpressing Bim were
exposed to WEHI-539, the vast majority of cells died shortly
after completing mitosis. These observations indicate that in
the absence of adequate pro-survival activity, mitosis itself
is sufficiently stressful to cause apoptosis. One possible trig-
ger for mitosis-specific stress is telomere deprotection, a
phenomenon whereby mitotic Aurora B kinase activity
displaces TRF2 from telomeres, giving rise to an exposed
telomere that is recognized by DNA damage response path-
ways [50,59]. Consistent with this notion, we previously
showed that overexpression of TRF2 or inhibition of Aurora
B suppresses mitotic apoptosis in Bcl-xL/Mcl-1-deficient
cells [12]. Here, we confirm this in that inhibition of Aurora
B delayed apoptosis in Mcl-1RNAi cells exposed to WEHI-
539. However, whether telomere deprotection is sufficient
to account for apoptosis in cells with weakened pro-survival
function remains to be seen. Indeed, this is a very intriguing
phenomenon that warrants further investigation. Interest-
ingly, a prolonged mitotic arrest results in mitophagy,
reduction in ATP levels and activation of AMPK, and a
metabolic switch from oxidative respiration to glycolysis
[11]. One possibility therefore is that mitosis-dependent
changes in metabolism and/or mitochondrial function
could also contribute to mitotic stress that is sufficientto induce apoptosis in cells with weakened pro-survival
function.
3.3. Identification of patients likely to benefit from
antimitotic/Bcl-xL inhibitor combinations
The taxanes and other antimitotic agents are vitally impor-
tant chemotherapy agents. Yet exactly how they yield
patient benefit remains obscure. Recently, the Mps1 inhibitor
NTRC 0066-0 was shown to potentiate the anti-tumour
activity of docetaxel in a mouse model of triple-negative
breast cancer [60]. Strikingly, however, the Mps1 inhibitor
alone had little effect, strongly suggesting that docetaxel’s
anti-tumour activity is via a mitotic mechanism. Indeed, an
analysis of breast cancer biopsies indicates that tumour
responses correlate with abnormal mitoses observed shortly
after taxol infusion [61]. Here, we show that Bcl-xL is a
potent pro-survival factor in this context: over a range of
clinically relevant taxol concentrations, WEHI-539 enhanced
apoptosis by both accelerating death in mitosis and by elevat-
ing the frequency of apoptosis following an abnormal
mitosis. These observations support and extend previous
reports showing that Navitoclax enhances cell death in
response to antimitotic agents [18,21,37,62,63]. Together,
these observations make a compelling case for exploring
Bcl-xL inhibitors in combination with taxanes in order to
enhance antimitotic chemotherapy. However, such combi-
nations will inevitably come with an increased toxicity
profile. Indeed, Bcl-xL is a molecular clock in platelets, defin-
ing their lifespan [64,65]. Consequently, Bcl-xL inhibitors
induce thrombocytopenia [66,67], and while this can be ame-
liorated clinically, judicious use will be required to open up a
useful therapeutic window. Interestingly, ovarian cancers
with relatively high Bcl-xL levels are less responsive to
taxane-based therapy, and ovarian cancer cell lines with
higher Bcl-xL/Mcl-1 ratios showed higher Bliss sum values
when treated with Navitoclax and taxol [45]. Taken together
with our observations, this suggests that patients whose
tumours have high Bcl-xL/Mcl-1 ratios might be good
candidates for Bcl-xL inhibitor trials in combination with
antimitotic agents. Similarly, early-phase clinical trials evalu-
ating novel mitotic blockers (e.g. those targeting Plk1 and
Cenp-E) might also benefit by pre-selecting patients with
high Bcl-xL/Mcl-1 ratios and exploring combinations with
Bcl-xL inhibitors. Conversely, exploring Bcl-xL inhibitors
may be less promising in the context of mitotic drivers
unless patients whose tumours have low Mcl-1 levels can
be identified.4. Material and methods
4.1. Cell lines
Parental RKO and DLD-1 cells, plus RKO Flp-In T-Rex
derivatives expressing Bim, Myc-tagged Bcl-xL and GFP-
tagged Mcl-1, were as described [12,49,68]. All lines were
cultured in DMEM plus 10% fetal calf serum (Life Technol-
ogies), 100 U ml21 penicillin, 100 U ml21 streptomycin and
2 mM glutamine (all from Sigma), then maintained at 378C
in a humidified 5% CO2 atmosphere. A stable RKO line
harbouring a tetracycline-inducible GFP-tagged Bcl-xL was
generated as described [69]. In brief, a Bcl-xL cDNA [12]
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gen) then co-transfected with pOG44 into Flp-In T-Rex RKO
cells using Lipofectamine Plus (Thermofisher). Stable inte-
grants were selected in 400 mg ml21 hygromycin B (Roche)
and 8 mg ml21 blasticidin (Melford), colonies pooled and
expanded to create an isogenic population. To synchronize
cells in S-phase, cells were treated with 2 mM thymidine for
16 h.
4.2. Small molecule inhibitors
The following drugs were dissolved in DMSO and stored at
2208C: WEHI-539 [32] (Apexbio); taxol (Sigma); nocodazole
(Sigma); AZ138 [8] (AstraZeneca)); AZ3146 [43] (AstraZe-
neca); BI 2536 [38] (Boehringer Ingelheim); GSK923295
[39,70]; MLN8054 [41] (Millennium Pharmaceuticals);
ZM447439 [42] (Tocris); A-1210477 [31] (Medchemexpress).
Tetracycline (Sigma) was dissolved in water, stored at
2208C, and used at concentrations indicated in the figure
legends. Thymidine (Sigma) was dissolved in PBS at a
concentration of 200 mM, and stored short-term at 48C.
4.3. RNAi
For RNAi-mediated inhibition, cells were plated in mclearw
96-well plates (Greiner Bio-One) then transfected with a final
concentration of 66 nM siRNA using DharmaFECT 1 trans-
fection reagent (Dharmacon) in Opti-MEM media (Life
Technologies). siRNAs were ON-TARGETplus SMARTpools
(Dharmacon) as described [12] containing oligonucleotides
with the following sequences: Bcl-xL (50-GGACAGCAUAUC
AGAGCUU-30, 50-GAAAUGACCAGACACUGAC-30, 50-CCU
ACAAGCUUUCCCAGAA-30, 50-UUAGUGAUGUGGAAGA
GAA-30), Mcl-1(50 CGAAGGAAGUAUCGAAUUU-30, 50-GA
UUAUCUCUCGGUACCUU-30, 50-GAAGGUGGCAUCAGG
AAUG-30, 50-GGUUUGGCAUAUCUAAUAA-30), non-targeting
control (50- UGGUUUACAUGUCGACUAA-30, 50-UGGUUU
ACAUGUUGUGUGA-30, 50-GGUUUACAUGUUUUCUGA-30,
50-UGGUUUACAUGUUUUCCUA-30).
4.4. Proliferation and apoptosis assays
To measure apoptosis induction and proliferation and to per-
form cell fate profiling, 1  105 cells were seeded per well in
mclear 96-well plates (Greiner Bio-One) and IncuCyte Kinetic
Caspase-3/7 Apoptosis Assay Reagent (Essen BioScience)
added. Note that this cell-permeable reagent consists of a cas-
pase-3/7 recognition motif (DEVD) coupled to a DNA
intercalating dye. Upon cleavage by activated caspase-3/7,
the liberated dye binds nuclear DNA and emits green fluor-
escence [71]. Fluorescence values were then normalized to
control wells on the same plate which exhibited maximum
apoptosis yielding percentage apoptosis values which were
plotted. Note also that to maximize fluorescence detection,
DMEM was replaced with Leibovitz’s L-15 (Sigma-Aldrich).
Cells were then imaged using an IncuCyte ZOOM (Essen Bio-
Science) equipped with a 20 objective and maintained at
378C in a humidified 5% CO2 atmosphere. Phase contrast
and fluorescence images with two to four images per well
were collected every 10–30 min and IncuCyte ZOOM soft-
ware used in real-time to measure confluency, as a proxy
for proliferation, and apoptosis, respectively. Image
sequences were then exported in MPEG-4 format andanalysed manually to generate cell fate profiles [8].
IncuCyte ZOOM data and timing data were imported into
PRISM 6 (GraphPad) for statistical analysis and presentation.
Note that zero hours on the fate profiles represent either
when cells entered mitosis or when imaging was started;
see individual figure legends for details.
4.5. Immunoprecipitation
Flp-In T-Rex RKO cells harbouring an inducible GFP-tagged
Bcl-xL transgene were seeded in 6-well plates and
100 ng ml21 tetracycline added overnight. 10  105 cells
were then harvested and lysed in 1 ml of buffer containing
0.1% Triton X-100, 100 mM NaCl, 10 mM Tris pH 7.4,
1 mM EDTA, 1 mM EGTA, 20 mM b-glycerophosphate,
10 mM NaF and protease/phosphatase inhibitors (Roche).
The lysate was then clarified by centrifugation at 16 000g
for 20 min at 48C. To 1 ml of supernatant, 30 mg of a GST-
GFP-nanotrap fusion protein was added [49,72] along with
glutathione sepharose beads (Amintra). After incubation at
48C with rotation for 2 h, beads were harvested by centrifu-
gation and washed five times with lysis buffer. Bound
proteins were eluted by boiling in sample buffer (0.35 M
Tris pH 6.8, 0.1 g ml21 sodium dodecyl sulfate, 93 mg ml21
dithiothreitol, 30% glycerol, 50 mg ml21 bromophenol blue)
then resolved by SDS-PAGE.
4.6. Immunoblotting
Following SDS-PAGE, proteins were electroblotted onto
Immobilon-P membranes. Following blocking in 5% dried
skimmed milk (Marvel) dissolved in TBST (50 mM Tris
pH 7.6, 150 mM NaCl, 0.1% Tween-20), membranes were
incubated overnight at 48C with the following primary anti-
bodies diluted in TBST: 54H6 (Rabbit anti-Bcl-xL, 1 : 1000;
Cell Signalling Technology), S-19 (Rabbit anti-Mcl-1, Santa
Cruz Biotechnology), sheep anti-Tao1 (1 : 3000 [73]), rabbit
anti-Bim (1 : 500; BD Biosciences), mouse anti-Bad (1 : 1000;
Santa Cruz), rabbit anti-Bid (1 : 1000; Cell Signalling),
mouse anti-Bax (1 : 1000; BD BioSciences), mouse anti-Bak
(1 : 1000; Calbiochem), 4A6 (mouse anti-Myc tag; 1 : 1000;
Millipore) and GFP (Rabbit anti-GFP; 1 : 1000; Cell Signal-
ling). Membranes were then washed three times in TBST
and incubated for at least 1 h with appropriate horseradish-
peroxidase-conjugated secondary antibodies (Zymed). After
washing in TBST, bound secondary antibodies were detected
using either EZ-ECL Chemiluminescence Reagent (Biological
Industries) or Luminata Forte Western HRP Substrate
(Millipore) and a Biospectrum 500 imaging system (UVP).
4.7. Statistical methods and Bliss independence analysis
PRISM v. 6 (GraphPad) was used for statistical analysis, with
non-parametric Mann–Whitney U-tests for all figures,
where *p, 0.05, **p, 0.01, ***p, 0.001, #p, 0.0001, n.s.:
p. 0.05. Lines on scatterplots show mean and interquartile
ranges. Combination synergy of WEHI-539 with antimitotic
agents was determined by Bliss independence analyses
[44,45]. A Bliss expectation for a combined response (C )
was calculated by the equation: C ¼ (A þ B) 2 (A  B),
where A and B are the percentage apoptosis induced by
drug A and B at a given dose. The difference between the
Bliss expectation and the extent of apoptosis observed is the
rsob.royalsocietypublishing
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dose matrix to generate a Bliss sum, where a value equal to
zero indicates that the combination is additive, a value
greater than zero indicates synergy, while a Bliss sum of
less than zero indicates antagonism.
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